Health & Fitness
Health and Fitness
Health and Fitness
Wed, May 16, 2012Tue, May 15, 2012Mon, May 14, 2012Sun, May 13, 2012Sat, May 12, 2012Fri, May 11, 2012Thu, May 10, 2012Wed, May 9, 2012Tue, May 8, 2012Mon, May 7, 2012Sat, May 5, 2012Fri, May 4, 2012Thu, May 3, 2012Wed, May 2, 2012Keryx Biopharmaceuticals to Present at The 11th Annual JMP Securities Research Conference
Published in Health and Fitness on Thursday, May 10th 2012 at 5:35 GMT by Market Wire
Keryx Biopharmaceuticals to Present at The 11th Annual JMP Securities Research Conference -- NEW YORK, May 10, 2012 /PRNewswire/ --
Keryx Biopharmaceuticals to Present at The 11th Annual JMP Securities Research Conference
Presentation Scheduled for Tuesday, May 15 at 12:00 noon PT
NEW YORK, May 10, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: [ KERX ]) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 11th Annual JMP Securities Research Conference, which will be held at the Ritz Carlton Hotel in San Francisco. Mr. Bentsur's presentation is scheduled to take place on Tuesday, May 15, 2012 at 12:00 noon Pacific Time (3:00 p.m. Eastern).
A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at [ http://investors.keryx.com ]. An archived version of the webcast will be available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.
KERYX CONTACT:
Lauren Fischer
Director – Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: [ lfischer@keryx.com ]
SOURCE Keryx Biopharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.keryx.com ]
